Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis

HIGHLIGHTS

• who: Persistence on Therapy and collaborators from the Departments of Medicine and Neurology, of Melbourne and Royal Melbourne Hospital, Melbourne, Australia, Department of Neurology, Royal MelbourneEditor: Tobias Derfuss, University Hospital Basel, Switzerland have published the paper: Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis, in the Journal: PLOS ONE | www.plosone.org of May/21,/2013
• what: [8] Similarly, the annual discontinuation rates due to reported adverse events were marginally higher in the study compared to the PRISMS trial (3% and 1.5-2.4 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.